Targeting IgE in Severe Atopic Dermatitis with a Combination of Immunoadsorption and Omalizumab
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
Patients with atopic dermatitis (AD) tend to have greatly elevated levels of serum immunoglobulin E (IgE). However, the role of IgE in the pathogenesis of AD is debated. This investigator-initiated open-label pilot study evaluates an anti-IgE-treatment approach by combining extracorporeal immunoadsorption and anti-IgE antibody omalizumab in 10 patients with severe, therapy-refractory AD. IgE levels decreased after immunoadsorption and decreased continuously in all patients during anti-IgE therapy. The reverse trend was observed during 6 months follow-up without treatment. In parallel with these observations, an improvement in AD was observed during the treatment period, with aggravation during follow-up. Further research is needed, based on the principle of reducing IgE levels in order to improve clinical symptoms, using a combination anti-IgE treatment approach, adjusted according to IgE levels.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“clinical improvement was shown in a small series of patients using omalizumab and/or immunoadsorption109–112.”
From Atopic dermatitis: an expanding therapeutic pipeline for a complex disease (2022) · cites this paper as [109]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Williams, H. C., Leung, D. Y. M., Thestrup‐Pedersen, K., & David, T. J. (2000) · Cited by 4,599
Severity Scoring of Atopic Dermatitis: The SCORAD Index
(2009) · Dermatology · doi:10.1159/000247298 · Cited by 2,273
Bieber, T. (2008) · New England Journal of Medicine · doi:10.1056/nejmra074081 · Cited by 1,780
Omalizumab for the Treatment of Chronic Idiopathic or Spontaneous Urticaria
Maurer, M., Rosén, K., Hsieh, H.-J., Saini, S., Grattan, C., Gimenéz-Arnau, A., Agarwal, S., Doyle, R., Canvin, J., Kaplan, A., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215372 · Cited by 1,105 · cited 1×
“Omalizumab is a recombinant DNA-derived IgG1 humanized (from mouse) monoclonal antibody selectively binding to human IgE and approved by the FDA and international regulatory agencies for patients with severe allergic asthma and, recently, for chronic spontaneous urticaria (14–16).”
BackgroundOmalizumab for asthma in adults and children
Normansell, R., Walker, S., Milan, S. J., Walters, E. H., & Nair, P. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003559.pub4 · Cited by 651 · cited 1×
“In addition, the high cost of immunoadsorption (24) and omalizumab (25) therapy limit their widespread use and currently justify a respective treatment only in patients with severe recalcitrant AD.”
BackgroundKakinuma, T., Nakamura, K., Wakugawa, M., Mitsui, H., Tada, Y., Saeki, H., Torii, H., Asahina, A., Onai, N., Matsushima, K., et al. (2001) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2001.113237 · Cited by 575
Kaplan, A., Ledford, D., Ashby, M., Canvin, J., Zazzali, J. L., Conner, E., Veith, J., Kamath, N., Staubach, P., Jakob, T., et al. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.05.013 · Cited by 573
Metz, M., Ohanyan, T., Church, M. K., & Maurer, M. (2014) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2013.08.011 · Cited by 274
(2006) · Springer eBooks · doi:10.1007/3-540-29856-8 · Cited by 273
Self-citationInvited Review Article : Atopic Dermatitis
Bieber, T. R. M. (2010) · Annals of Dermatology · Cited by 255
Heil, P. M., Maurer, D., Klein, B., Hultsch, T., & Stingl, G. (2010) · JDDG: Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/j.1610-0387.2010.07497.x · Cited by 197
Treatment of recalcitrant atopic dermatitis with omalizumab
Lane, J. E., Cheyney, J. M., Lane, T. N., Kent, D. E., & Cohen, D. J. (2006) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2005.09.030 · Cited by 188 · cited 1×
“…in AD (19), studies with omalizumab typically had very ambivalent re-sults: some showed a benefit for patients with AD (4, 5), some rejected this treatment approach (6, 7) and others discussed the high IgE level in AD as a possible limitation for a promising use of this anti-IgE antibody (8–10).”
Failure of omalizumab for treatment of severe adult atopic dermatitis
Krathen, R. A., & Hsu, S. (2005) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2005.02.014 · Cited by 172 · cited 1×
“…in AD (19), studies with omalizumab typically had very ambivalent re-sults: some showed a benefit for patients with AD (4, 5), some rejected this treatment approach (6, 7) and others discussed the high IgE level in AD as a possible limitation for a promising use of this anti-IgE antibody (8–10).”
Fujisawa, T., Fujisawa, R., Kato, Y., Nakayama, T., Morita, A., Katsumata, H., Nishimori, H., Iguchi, K., Kamiya, H., Gray, P. W., et al. (2002) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2002.126079 · Cited by 170
Transfer of Symptomatic Peanut Allergy to the Recipient of a Combined Liver-And-Kidney Transplant
Legendre, C., Caillat-Zucman, S., Samuel, D., Morelon, S., Bismuth, H., Bach, J.-F., & Kreis, H. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709183371204 · Cited by 165
Low-dose anti-IgE therapy in patients with atopic eczema with high serum IgE levels
Belloni, B., Ziai, M., Lim, A., Lemercier, B., Sbornik, M., Weidinger, S., Andres, C., Schnopp, C., Ring, J., Hein, R., et al. (2007) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2007.08.060 · Cited by 157
Self-citationEfficacy of anti-IgE therapy in patients with atopic dermatitis
Vigo, P. G., Girgis, K. R., Pfuetze, B. L., Critchlow, M. E., Fisher, J., & Hussain, I. (2006) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2005.12.045 · Cited by 152
Efficacy of omalizumab in the treatment of atopic dermatitis: A pilot study
Sheinkopf, L. E., Rafi, A. W., Do, L. T., Katz, R. M., & Klaustermeyer, W. B. (2008) · Allergy and Asthma Proceedings · doi:10.2500/aap.2008.29.3160 · Cited by 150 · cited 1×
“…in AD (19), studies with omalizumab typically had very ambivalent re-sults: some showed a benefit for patients with AD (4, 5), some rejected this treatment approach (6, 7) and others discussed the high IgE level in AD as a possible limitation for a promising use of this anti-IgE antibody (8–10).”
Does “autoreactivity” play a role in atopic dermatitis?
Tang, T. S., Bieber, T., & Williams, H. C. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.02.002 · Cited by 146 · cited 1×
“It is believed that there are different types (21) or phases (1) of AD with differing elevations of IgE; some might be even influenced by IgE autoantibodies (22, 23).”
BackgroundSerum IgE Autoantibodies Target Keratinocytes in Patients with Atopic Dermatitis
Altrichter, S., Kriehuber, E., Moser, J., Valenta, R., Kopp, T., & Stingl, G. (2008) · Journal of Investigative Dermatology · doi:10.1038/jid.2008.80 · Cited by 113 · cited 1×
“It is believed that there are different types (21) or phases (1) of AD with differing elevations of IgE; some might be even influenced by IgE autoantibodies (22, 23).”
BackgroundOmalizumab: a monoclonal anti-IgE antibody.
Belliveau, P. (2005) · PubMed Central · Cited by 107
Atopic dermatitis: Therapeutic concepts evolving from new pathophysiologic insights
Jung, T., & Stingl, G. (2008) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2008.09.042 · Cited by 75
The development of food allergy after liver transplantation
Boyle, R. J., Hardikar, W., & Tang, M. L. K. (2005) · Liver Transplantation · doi:10.1002/lt.20368 · Cited by 71
Kim, D. H., Park, K. Y., Kim, B. J., Kim, M. N., & Mun, S. K. (2013) · Clinical and Experimental Dermatology · doi:10.1111/j.1365-2230.2012.04438.x · Cited by 70 · cited 1×
“…reduction in IgE levels in AD (19), studies with omalizumab typically had very ambivalent re-sults: some showed a benefit for patients with AD (4, 5), some rejected this treatment approach (6, 7) and others discussed the high IgE level in AD as a possible limitation for a promising use of this…”
Improvement of treatment-refractory atopic dermatitis by immunoadsorption: A pilot study
Kasperkiewicz, M., Schmidt, E., Frambach, Y., Rosé, C., Meier, M., Nitschke, M., Falk, T. M., Reich, K., Ludwig, R. J., & Zillikens, D. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.07.042 · Cited by 56
Brown, C. C., Haringman, N., Davies, C., Gore, C., Hussain, M. J., Mieli‐Vergani, G., Vergani, D., Warner, J. O., Marks, S. D., & Boyle, R. J. (2012) · Pediatric Allergy and Immunology · doi:10.1111/pai.12011 · Cited by 38 · cited 1×
“Several previous publications have described a possible transfer of the donor’s IgE-mediated allergies to the recipient of liver transplants (26–28) and, although this phenomenon cannot yet be explained clearly, an involvement of the liver in IgE-mediated allergies is suggested (29, 30).”
BackgroundNew developments in transplant-acquired allergies
Özdemir, Ö. (2013) · World Journal of Transplantation · doi:10.5500/wjt.v3.i3.30 · Cited by 37 · cited 1×
“Several previous publications have described a possible transfer of the donor’s IgE-mediated allergies to the recipient of liver transplants (26–28) and, although this phenomenon cannot yet be explained clearly, an involvement of the liver in IgE-mediated allergies is suggested (29, 30).”
BackgroundDiagnosis and Treatment of Patients with Autoimmune Bullous Disorders in Germany
Schmidt, E., & Zillikens, D. (2011) · Dermatologic Clinics · doi:10.1016/j.det.2011.06.007 · Cited by 25 · cited 1×
“In addition, the high cost of immunoadsorption (24) and omalizumab (25) therapy limit their widespread use and currently justify a respective treatment only in patients with severe recalcitrant AD.”
BackgroundTransference of Food Allergy After Adult Liver Transplantation
Vagefi, P. A., Blazick, E. A., Hamilos, D. L., Ades, A., Cosimi, A. B., & Hertl, M. (2009) · Transplantation · doi:10.1097/tp.0b013e3181a27acc · Cited by 20 · cited 1×
“Several previous publications have described a possible transfer of the donor’s IgE-mediated allergies to the recipient of liver transplants (26–28) and, although this phenomenon cannot yet be explained clearly, an involvement of the liver in IgE-mediated allergies is suggested (29, 30).”
Background(2000) · Time to knit · doi:10.1016/j.yped.2013.05.042 · Cited by 13
Quantitation of serum IgE by using chimeras of human IgE receptor and avian immunoglobulin domains
Braren, I., Greunke, K., Pilette, C., Mempel, M., Grunwald, T., Bredehorst, R., Ring, J., Spillner, E., & Ollert, M. W. (2010) · Analytical Biochemistry · doi:10.1016/j.ab.2010.12.013 · Cited by 12 · cited 2×
“On every visit, biologically active IgE (free IgE) and TARC were quantified according to standardized protocols (R&D Systems, Abingdon, UK) (17, 18), the severity of AD was documented with the SCORAD index, and the patient’s personal evaluation on the VAS and standardized photographs were taken.”
MethodSelf-citationKerzel, S., Zemlin, M., Rogosch, T., Ollert, M. W., Renz, H. E., Klaus, G., & Maier, R. F. (2011) · Klinische Pädiatrie · doi:10.1055/s-0031-1287824 · Cited by 7 · cited 1×
“On every visit, biologically active IgE (free IgE) and TARC were quantified according to standardized protocols (R&D Systems, Abingdon, UK) (17, 18), the severity of AD was documented with the SCORAD index, and the patient’s personal evaluation on the VAS and standardized photographs were taken.”
MethodSelf-citationSerum IgE Autoantibodies Target Keratinocytes in Patients with Atopic Dermatitis
THIERS, B. H. (2009) · Yearbook of Dermatology and Dermatologic Surgery · doi:10.1016/s0093-3619(08)79176-7 · Cited by 6
Research works printed but not linked: 3
- [2]2. Bieber T. Atopic dermatitis. Ann Dermatol 2010; 22: 125-137.
- [5]5. Kim DH, Park KY, Kim BJ, Kim MN, Mun SK. Antiimmunoglobulin E in the treatment of refractory atopic dermatitis. Clin Exp Dermatol 2013; 38: 496-500.
- [21]21. Jung T, Stingl G. Atopic dermatitis: therapeutic concepts evolving from newpathophysiologic insights. J Allergy Clin Immunol 2008; 122: 1074-1081.
Cited by
Wollenberg, A., Barbarot, S., Bieber, T., Christen‐Zaech, S., Deleuran, M., Fink‐Wagner, A., Gieler, U., Girolomoni, G., Lau, S., Muraro, A., et al. (2018) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.14891 · Cited by 1,181
Self-citationWollenberg, A., Barbarot, S., Bieber, T., Christen‐Zaech, S., Deleuran, M., Fink‐Wagner, A., Gieler, U., Girolomoni, G., Lau, S., Muraro, A., et al. (2018) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.14888 · Cited by 684
Self-citationAtopic dermatitis: an expanding therapeutic pipeline for a complex disease
Bieber, T. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00266-6 · Cited by 623
Therapeutic pipeline for atopic dermatitis: End of the drought?
Paller, A. S., Kabashima, K., & Bieber, T. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.07.006 · Cited by 192
Systemic Treatment of Adult Atopic Dermatitis: A Review
Megna, M., Napolitano, M., Patruno, C., Villani, A., Balato, A., Monfrecola, G., Ayala, F., & Balato, N. (2017) · Dermatology and Therapy · doi:10.1007/s13555-016-0170-1 · Cited by 159
“found a relationship between reduction in free IgE levels and AD clinical improvement by combining extracorporeal immunoadsorption and omalizumab therapy in ten patients with severe and therapy-refractory AD [125], whereas Toledo et al.”
Background
Metadata
- Authors
- Zink, A., Gensbaur, A., Zirbs, M., Seifert, F., Suarez, I., Mourantchanian, V, Weidinger, S., Mempel, M., Ring, J., & Ollert, M.
- Affiliations
- Technical University of Munich (DE)
- TUM Klinikum (DE)
- Christian-Albrechts-Universität zu Kiel (DE)
- Helmholtz Munich (DE)
- University of Southern Denmark (DK)
- Venue
- Acta Dermato Venereologica
- Published
- 2016
- Volume
- 96
- Issue
- 1
- Pages
- 72-76
- ISSN
- 0001-5555 (ISSN-L)
- OpenAlex
- W1817989193
- Cited by
- 67
- References
- 32
- Citations by year
- 2025: 5 · 2024: 1 · 2023: 6 · 2022: 3 · 2021: 10 · 2020: 2 · 2019: 9 · 2018: 10 · 2017: 11 · 2016: 9
- FWCI
- 11.57
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- Locations
- Acta Dermato Venereologica (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- University of Southern Denmark Research Portal (University of Southern Denmark) (publishedVersion, other-oa)
- PuSH - Publication Server of Helmholtz Zentrum München (submittedVersion, cc-by-nc)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion, other-oa)
- mediaTUM (Technical University of Munich) (submittedVersion)
- Site cant be reached (submittedVersion, cc-by-nc)
- Funders
- Deutsche Forschungsgemeinschaft
- Technische Universität München
- Topics
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
- Health Sciences › Medicine › Dermatology › Contact Dermatitis and Allergies
- Keywords
- atopic dermatitis, immunoglobulin E, omalizumab, extracorporeal immunoadsorption, anti-IgE therapy, IgE levels, treatment response
- MeSH terms
- Omalizumab, Adult, Aged, Blood Component Removal, Combined Modality Therapy, Dermatitis, Atopic, Female, Humans, Immunoglobulin E, Immunosorbent Techniques, Male, Middle Aged, Pilot Projects, Remission Induction, Severity of Illness Index, Time Factors, Biomarkers, Treatment Outcome, Disease Progression, Anti-Allergic Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.